Unpacking the 8 Key Risk Factors for Breast Cancer

Breast cancer is not a single disease but a heterogeneous group of malignancies with diverse biological behaviors, molecular profiles, and clinical outcomes. Advances in genomic profiling and tumor biology have led to the recognition of at least eight distinct molecular subtypes—each defined by unique patterns of gene expression, protein receptor status, and driver alterations. Understanding these subtypes is critical for risk stratification, treatment selection, and prognostication.

The first major subtype is hormone receptor–positive (HR+), HER2-negative breast cancer—comprising approximately 70% of cases. These tumors express estrogen receptor (ER) and/or progesterone receptor (PR), but lack overexpression or amplification of the HER2/neu oncogene. They typically exhibit luminal epithelial differentiation and respond well to endocrine therapies such as aromatase inhibitors or selective estrogen receptor modulators.

HER2-positive (HER2+) breast cancer accounts for roughly 15–20% of invasive cases. Defined by amplification of the ERBB2 gene or overexpression of the HER2 protein, this subtype is highly proliferative and historically carried a poor prognosis—though targeted anti-HER2 agents like trastuzumab, pertuzumab, and antibody–drug conjugates have dramatically improved survival.

Triple-negative breast cancer (TNBC), representing 10–15% of cases, lacks expression of ER, PR, and HER2. It is biologically aggressive, often associated with BRCA1 germline mutations, and enriched for basal-like features—including high-grade histology, frequent TP53 mutations, and immune infiltration. While chemotherapy remains foundational, recent advances include PARP inhibitors for BRCA-mutated disease and immune checkpoint inhibitors for PD-L1–positive metastatic TNBC.

Luminal A and Luminal B are further refinements within the HR+/HER2− category. Luminal A tumors are typically low-grade, strongly ER-positive, Ki-67–low (<14%), and have excellent long-term outcomes with endocrine therapy alone. Luminal B tumors show higher proliferation (Ki-67 ≥20%), may be PR-low or negative, and often benefit from combined endocrine and chemotherapy regimens.

HER2-enriched (non-luminal) tumors are HR-negative but HER2-positive—distinct from HR+/HER2+ disease due to their lack of hormone receptor signaling. They rely predominantly on HER2-driven pathways and respond robustly to dual HER2 blockade.

The claudin-low subtype is rare (<5%) and characterized by low expression of tight junction proteins (e.g., claudin-3, -4, -7), epithelial–mesenchymal transition (EMT) signatures, stem-cell–like properties, and immunosuppressive microenvironments. It overlaps significantly with metaplastic and some basal-like TNBCs and remains challenging to treat.

Normal-like breast cancer mimics gene expression patterns seen in healthy mammary tissue. Though clinically indolent in many cases, its classification remains controversial due to technical artifacts in gene expression profiling and potential contamination with normal stromal cells. Its therapeutic implications are still under active investigation.

Finally, the recently described apocrine subtype—defined by androgen receptor (AR) expression, lipid metabolism gene upregulation, and frequent PIK3CA mutations—represents a small but therapeutically relevant subset. Early-phase trials are evaluating AR antagonists in AR-positive, triple-negative disease.